The three-dimensional organization of the genome is linked to its function. For example, regulatory elements such as transcriptional enhancers control the spatio-temporal expression of their target genes through physical contact, often bridging considerable (in some cases hundreds of kilobases) genomic distances and bypassing nearby genes. The human genome harbors an estimated one million enhancers, the vast majority of which have unknown gene targets. Assigning distal regulatory regions to their target genes is thus crucial to understand gene expression control. We developed Promoter Capture Hi-C (PCHi-C) to enable the genome-wide detection of distal promoter-interacting regions (PIRs), for all promoters in a single experiment. In PCHi-C, highly complex Hi-C libraries are specifically enriched for promoter sequences through in-solution hybrid selection with thousands of biotinylated RNA baits complementary to the ends of all promoter-containing restriction fragments. The aim is to then pull-down promoter sequences and their frequent interaction partners such as enhancers and other potential regulatory elements. After high-throughput paired-end sequencing, a statistical test is applied to each promoter-ligated restriction fragment to identify significant PIRs at the restriction fragment level. We have used PCHi-C to generate an atlas of long-range promoter interactions in dozens of human and mouse cell types. These promoter interactome maps have contributed to a greater understanding of mammalian gene expression control by assigning putative regulatory regions to their target genes and revealing preferential spatial promoter-promoter interaction networks. This information also has high relevance to understanding human genetic disease and the identification of potential disease genes, by linking non-coding diseaseassociated sequence variants in or near control sequences to their target genes.
Introduction
Accumulating evidence suggests that the three-dimensional organization of the genome plays an important functional role in a range of nuclear processes, including gene activation 1, 2, 3 , repression 4, 5, 6, 7, 8 , recombination 9, 10 , DNA repair 11 , DNA replication 12, 13 , and cellular senescence 14 . Distant enhancers are found in close spatial proximity to the promoters they regulate 15, 16, 17 , which is essential for proper spatio-temporal gene expression control. Enhancer deletions show that distal enhancers are essential for target gene transcription 18, 19, 20, 21, 22 , and 'forced chromatin looping' demonstrates that engineered tethering between an enhancer and its target promoter in the Hbb locus is sufficient to drive transcriptional activation 23 . Further, genome rearrangements that bring genes under the control of ectopic enhancers can result in inappropriate gene activation and disease 24, 25, 26 . Together, these examples illustrate that promoter-enhancer interactions are essential for gene control and require tight regulation to ensure appropriate gene expression. The human and mouse genomes are each estimated to harbor around one million enhancers. For the vast majority of these enhancers, target genes are unknown, and the 'rules of engagement' between promoters and enhancers are poorly understood. Assigning transcriptional enhancers to their target genes thus remains a major challenge in deciphering mammalian gene expression control.
DNA Fragmentation
1. Transfer 50.5 µg of sample in a new tube and add TLE buffer to a final volume of 655 µL. Split sample into 5 sonication vials (see Table of Materials) by adding 130 µL of library (10 µg) to each vial. Shear to a size of ~400 bp in an ultra-sonicator (see Table of Materials) using the following parameters: duty factor: 10%; peak incident power (w): 140; cycles per burst: 200; time: 55 s. 2. Collect sonicated sample in a fresh 2 mL tube.
Double-sided SPRI-bead Size Selection
1. Mix SPRI (Solid Phase Reversible Immobilization) bead solution well by inverting, transfer 1.85 mL of bead solution to a new tube and bring to RT for 15 min. 2. Add 350 µL of water (molecular biology grade) to the sample (final volume 1 mL). 3. Add 600 µL of SPRI bead solution to the sample (total volume 1.6 mL; ratio of SPRI solution to DNA: 0.6 to 1), incubate for 5 min at RT, and spin sample in a benchtop centrifuge for 2-3 s to collect sample. 4. Open the lid, place the sample on the magnetic separation stand for 5 min, transfer clear supernatant into a new tube and discard beads. 5. Concentrate SPRI beads for the second size selection step: Transfer 930 µL of SPRI beads into a new tube, place on the magnetic separation stand for 5 min and discard clear supernatant. Re-suspend the beads in 310 µL of SPRI bead solution. 6. Add 300 µL of concentrated SPRI beads (step 10.5) to the sample (total volume 1.9 mL; ratio SPRI solution to DNA is now 0.9 to 1), incubate at RT for 5 min, and spin sample in a benchtop centrifuge for 2-3 s. Carefully open the lid, place the tube on the magnetic separation stand for 5 min, and discard supernatant. 7. Add 1 mL of freshly prepared 70% ethanol (vol/vol) to the sample tube on the magnetic separation stand, incubate for 30 s, and discard supernatant. Repeat twice. 8. Dry beads at 37 °C in a thermomixer (tube lid open) for no more than 5 min. Add 300 µL of TLE buffer to the sample, mix, and incubate for 10 min at room temperature. 9. Spin sample in a benchtop centrifuge for 2-3 s, open the lid and place the tube on the magnetic separation stand for 5 min. Transfer clear supernatant into a new tube and discard beads.
Biotin/Streptavidin Pull-down of Ligation Products
1. Prepare buffers: 1x TB buffer (5mM Tris-HCl pH 8.0; 0.5mM EDTA; 1 M NaCl; 0.05% Tween 20); 2x NTB buffer (10 mM Tris-HCl pH 8.0; 1 mM EDTA; 2 M NaCl); 1x NTB buffer (5 mM Tris-HCl pH 8.0; 0.5 mM EDTA; 1 M NaCl). 2. Add 200 µL of magnetic streptavidin-coupled beads (see Table of Materials) into a new tube, place it on the magnetic separation stand for 1 min and remove supernatant. 3. Wash beads twice with 500 µL of 1x TB buffer.
1. For each wash step during the biotin pull-down, end repair and removal of biotin at non-ligated DNA ends, dATP tailing, and adapter ligation steps, re-suspend the beads in the corresponding buffer, rotate at RT and 15 rpm for 3 min, spin the tube in a benchtop centrifuge for 2-3 s, place the tube on the magnetic separation stand for 3 min and remove supernatant.
4. Re-suspend beads in 300 µL of 2x NTB buffer. Mix beads and sample (600 µL total volume) and incubate at RT for 15 min on a rotating wheel at 3 rpm. 5. Reclaim beads on the magnetic separation stand for 3 min and remove the clear supernatant. Wash beads twice in 500 µL of 1x NTB buffer first and then in 200 µL of 1x ligation buffer. Re-suspend the beads in 50 µL of 10x ligation buffer.
Isolation of Promoter Fragment-containing Ligation Products
NOTE: The following steps are recommended to be done with SureSelect adapter kit and library (see Table of Materals).
1. Pre-warm 1.5 mL of wash buffer 2 per sample at 65 °C in advance. 2. Add 60 µL of streptavidin-coupled magnetic beads (see Table of Materials) into a new tube, place on the magnetic separation stand for 1 min and remove supernatant. 3. Wash beads three times with 200 µL of 1x binding buffer.
NOTE: For each wash step during the post-capture isolation of promoter-containing ligation products, re-suspend beads in the corresponding buffer, rotate for 3 min at RT and 15 rpm on a rotating wheel, softly spin the tube in a benchtop centrifuge for 2-3 s to collect sample, place the tube on the magnetic separation stand for 3 min, and remove supernatant. 4. Re-suspend beads in 200 µL of 1x binding buffer. Open the PCR machine and the PCR tube strip (while the PCR program is still running) and transfer the hybridization reaction into the tube with the magnetic beads. Incubate at RT for 30 min on a rotating wheel at 3 rpm. 5. Reclaim beads on the magnetic separation stand and remove the clear supernatant. Re-suspend beads into 500 µL of wash buffer 1, mix, and incubate for 15 min at 20 °C while shaking at 950 rpm in a thermomixer. 6. Reclaim beads on the magnetic separation stand for 3 min and remove the clear supernatant. Re-suspend beads into 500 µL of wash buffer 2, mix and incubate 10 min at 65 °C while shaking at 950 rpm in a thermomixer. Repeat step 17.5 twice more. 7. Reclaim beads on the magnetic separation stand, remove the clear supernatant and re-suspend beads in 200 µL of 1x restriction buffer 2.
Reclaim beads on the magnetic separation stand, remove supernatant and re-suspend beads into 30 µL of 1x restriction buffer 2. 
PCHi-C Library Amplification

Representative Results
Promoter Capture Hi-C has been used to enrich mouse 7, 34, 36, 39 and human 33, 35, 37, 38 Hi-C libraries for promoter interactions. A similar protocol (named HiCap) has been described by the Sandberg group 40 . Figure 1A shows the schematic workflow for Promoter Capture Hi-C. In the protocol described here, Hi-C libraries are generated using in-nucleus ligation 41 , which results in a significantly reduced number of spurious ligation products 42 . For PCHi-C, highly complex mouse or human Hi-C libraries are subjected to in-solution hybridization and capture using 39,021 biotinylated RNAs complementary to 22,225 mouse promoter-containing HindIII restriction fragments, or 37,608 biotinylated RNAs targeting 22,076 human promoter-containing HindIII restriction fragments, respectively. Promoter containing restriction fragments can be targeted at either or both ends by individual biotinylated RNAs ( Figure 1B) . We found that capture of both ends improved coverage of individual promoters ( Figure 1C ; raw sequence reads) nearly two-fold, as expected. Thus, whenever possible (i.e., in non-repetitive regions), we advise to use biotinylated RNAs complementary to both ends of a restriction fragment to be captured.
To assess PCHi-C library quality at an early stage during library preparation, we perform two controls after DNA ligation and purification, as previously described 31 . The first is to use specific primer pairs to amplify ligation products as in 3C 27 . We use primer pairs ( Table 1) to amplify cell-type invariant long-range ligation products, such as between the Myc gene and its known enhancers located approximately 2 Mb away (Figure 2A ) or between genes of the Hist1 locus (separated by 1.5 Mb), and between two regions located in close linear proximity ('short-range control').
The second quality control is carried out to determine the efficiency of biotin incorporation during Klenow-mediated fill-in of restriction site overhangs with biotin-dATP. Successful Klenow fill-in and subsequent blunt-end ligation results in the disappearance of the original restriction site between the DNA molecules of a ligation product, and in the case of HindIII in the formation of a new NheI recognition site ( Figure 2B ). The ratio of the HindIII to NheI digested ligation product is a direct readout of biotin incorporation efficiency. A poor quality Hi-C library will show a high level of HindIII digestion, whereas high-quality libraries have near-complete NheI digestion of ligation products ( Figure 2B ).
After Hi-C library preparation (i.e., after biotin-streptavidin pull down of size-selected Hi-C ligation products, adapter ligation and pre-capture PCR), the integrity and size distribution of the Hi-C library is assessed by Bioanalyzer ( Figure 2C) . The same control is carried out at the end of PCHi-C library preparation (i.e., after hybridization capture of promoter-containing ligation products and post-capture PCR). Comparison of the Hi-C and PCHi-C Bioanalyzer profiles shows that as expected, Hi-C libraries are much more concentrated than the corresponding PCHi-C libraries, but the size distribution of the libraries is highly similar, indicating that the capture step in PCHi-C does not introduce a size bias ( Figure  2C, D) .
. High-quality PCHi-C libraries contain between 70-90% 'valid pairs' (i.e., paired-end sequence reads between two restriction fragments that are not neighboring on the linear genomic map; Figure 3A, B) . Using the in-nucleus ligation protocol 41, 42 , the percentage of trans read pairs (i.e., paired-end sequence reads between two restriction fragments that are located on different chromosomes) are usually low, between 5 and 25%, reflecting the existence of chromosome territories, and indicating good library quality. Direct comparison of the percentage of 'valid pairs' between Hi-C libraries and their corresponding PCHi-C libraries 35 , shows that in all cases the percentage of valid pairs is higher in the PCHi-C libraries ( Figure 3B ). This is accompanied by a reduction in the percentage of non-valid 'same fragment internal' reads in PCHi-C ( Figure 3C) . This is expected, as the capture step not only enriches for promoter-containing ligation products, but also for restriction fragment ends, due to the position of the capture oligos on the restriction fragments (see Figure 1B) .
After HiCUP filtering, we determine the capture efficiency. PCHi-C libraries contain three types of valid sequence reads after HiCUP filtering: 1.) Promoter: genome reads (i.e., reads between a captured promoter fragment and a non-promoter HindIII restriction fragment anywhere in the genome) 2.) Promoter: promoter reads (reads between two captured promoter fragments) 3.) Genome: genome reads (background Hi-C ligation products where neither of the ligation product partners maps to a captured promoter). These are discarded prior to downstream analyses.
High-quality PCHi-C libraries have capture efficiencies (sum of categories 1 and 2 above) between 65-90% ( Figure 3D) . A direct comparison to Hi-C libraries shows that PCHi-C results in a ~15-fold enrichment for promoter-containing ligation products (Figure 3D) , in some cases 17-fold. This is close to the hypothetical maximum (19.6-fold) enrichment for PCHi-C, which is dependent on the percentage of the genome restriction fragments covered by the capture system. Greater enrichment can be achieved by designing capture systems targeting fewer restriction fragments 44, 45, 46 .
Analysis of promoter interactomes demonstrates cell type and lineage-specificity 33, 34, 35 , with pronounced changes during cellular differentiation 37, 38, 39 . Figures 4 and 5 show examples of lineage specificity and differentiation dynamics at specific promoters. For example, ALAD is constitutively expressed in all cells but its expression is upregulated in erythroblasts 47 . The ALAD promoter contacts several distal fragments in all hematopoietic cells and engages in additional interactions specifically in erythroblasts (Figure 4 ). IL-8 shows no statistically significant interactions in B cells, very few interactions in T cells, but dozens of interactions in cells of the myeloid lineage, including cell-type specific interactions in monocytes, neutrophils and megakaryocytes ( Figure 5 ). These examples demonstrate how PCHi-C can be used to unravel cell-type specific interactomes and identify promoter-interacting regions with regulatory potential. 
Human
Discussion
Modular design of Promoter Capture Hi-C
Promoter Capture Hi-C is designed to specifically enrich Hi-C libraries for interactions involving promoters. These interactions comprise only a subset of ligation products present in a Hi-C library.
Capture Hi-C can easily be modified to enrich Hi-C libraries for any genomic region or regions of interest by changing the capture system. Capture regions can be continuous genomic segments 44, 45, 46, 48 , enhancers that have been identified in PCHi-C ('Reverse Capture Hi-C' 35 ), or DNase I hypersensitive sites 49 . The size of the capture system can be adjusted depending on the experimental scope. For example, Dryden et al. target 519 bait fragments in three gene deserts associated with breast cancer 44 . The capture system by Martin et al. targets both continuous genomic segments ('Region Capture': 211 genomic regions in total; 2,131 restriction fragments) and selected promoters (3,857 gene promoters) 45 . SureSelect libraries are available in different size ranges: 1 kb to 499 kb (5, 806) , 500 kb to 2.9 Mb (5, 816) , and 3 Mb to 5.9 Mb (5,190-4,831). As each individual capture biotin-RNA is 120 nucleotides long, these capture systems accommodate a maximum of 4,158, 24,166 and 49,166 individual capture probes, respectively. This corresponds to 2,079, 12,083, and 24,583 targeted restriction fragments, respectively (note that the numbers for restriction fragments are lower bounds based on the assumption that two individual capture probes can be designed for every restriction fragment -in reality due to repetitive sequences this will not be the case for every restriction fragment (see also Figure 1B , C), resulting in a higher number of targetable restriction fragments for a constant number of available capture probes).
The protocol described here is based on the use of a restriction enzyme with a 6 bp recognition site to uncover long-range interactions. Using a restriction enzyme with a 4 bp recognition site for greater resolution of more proximal interactions is also possible 40, 49 .
Limitations of PCHi-C
One inherent limitation of all chromosome conformation capture assays is that their resolution is determined by the restriction enzyme used for the library generation. Interactions that occur between DNA elements located on the same restriction fragment are invisible to 'C-type' assays. Further, in PCHi-C, in some cases more than one transcription start site can be located on the same promoter-containing restriction fragment, and PIRs in some cases harbor both active and repressive histone marks, making it difficult to pinpoint which regulatory elements mediate the interactions, and to predict the regulatory output of promoter interactions. Using restriction enzymes with 4 bp recognition sites mitigates this issue but comes at the expense of vastly increased Hi-C library complexity (Hi-C libraries generated with 4 bp recognition site restriction enzymes are at least 100 times more complex than Hi-C libraries generated with 6 bp recognition site restriction enzymes), and the associated costs for next generation sequencing.
Another limitation is that the current PCHi-C protocol requires millions of cells as starting material, precluding the analysis of promoter interactions in rare cell types. A modified version of PCHi-C to enable the interrogation of promoter contacts in cell populations with 10,000 to 100,000 cells (for example cells during early embryonic development or hematopoietic stem cells) would therefore be a valuable addition to the Capture Hi-C toolbox.
Finally, like all methods that rely on formaldehyde fixation, PCHi-C only records interactions that are 'frozen' at the time point of fixation. Thus, to study the kinetics and dynamics of promoter interactions, methods such as super-resolution live cell microscopy are required alongside PCHi-C.
Methods to dissect spatial chromosome organization at high resolution
The vast complexity of chromosomal interaction libraries prohibits the reliable identification of interaction products between two specific restriction fragments with statistical significance. To circumvent this problem, sequence capture has been used to enrich either Hi-C , which contained around 5-8% valid reads after HiCUP filtering. Sahlen et al. have directly compared Capture-C to HiCap, which like PCHi-C uses Hi-C libraries for capture enrichment, in contrast to Capture-C which uses 3C libraries. Consistent with our findings, they found that Capture-C libraries are mainly composed of un-ligated fragments 40 . In addition, HiCap libraries had a higher complexity than Capture-C libraries 40 .
A variant of Capture-C, called next-generation Capture-C 52 (NG Capture-C) uses one oligo per restriction fragment end, as previously established in PCHi-C 33, 34 , instead of overlapping probes used in the original Capture-C protocol 50 . This increases the percentage of valid reads compared to Capture-C modestly, but NG Capture-C employs two sequential rounds of capture enrichment, and a relatively high number of PCR cycles (20 to 24 cycles in total, compared to 11 cycles typically for PCHi-C), which inevitably results in higher numbers of sequence duplicates and lower library complexity. In trial experiments during the optimization of PCHi-C, we found that the percentage of unique (i.e., not duplicated) read pairs was only around 15% when we used 19 PCR cycles (13 cycles pre-capture + 6 cycles post-capture; data not shown), however optimization to a lower number of PCR cycles, typically yields 75-90% unique read pairs. Thus, reducing the number of PCR cycles substantially increases the amount of informative sequence data.
A recent method combines ChIP with Hi-C to focus on chromosomal interactions mediated by a specific protein of interest (HiChIP 53 ). Compared to ChIA-PET 54 , which is based on a similar rationale, HiChIP data contains a higher number of informative sequence reads, allowing for higher-confidence interaction calling 53 . It will be very interesting to directly compare the corresponding HiChIP and Capture Hi-C data sets once they become available (for example HiChIP using an antibody against the cohesin unit Smc1a 53 with Capture Hi-C for all Smc1a bound restriction fragments) side by side. One inherent difference between these two approaches is that Capture Hi-C does not rely on chromatin immunoprecipitation, and therefore is capable of interrogating chromosomal interactions irrespective of protein occupancy. This enables comparison of 3D genome organization in the presence or absence of specific factor binding, as has been used to identify PRC1 as a key regulator of mouse ESC spatial genome architecture 7 .
PCHi-C and GWAS
Genome-wide association studies (GWAS) have revealed that greater than 95% of disease-associated sequence variants are located in noncoding regions of the genome, often at great distances to protein-coding genes 55 . GWAS variants are often found in close proximity to DNase I hypersensitive sites, which is a hallmark of sequences with potential regulatory activity. PCHi-C and Capture Hi-C have been used extensively to link promoters to GWAS risk loci implicated in breast cancer 44 , colorectal cancer 48 , and autoimmune disease 35, 45, 46 . A PCHi-C study on 17 different human hematopoietic cell types found SNPs associated with autoimmune disease were enriched in PIRs in lymphoid cells, whereas sequence variants associated with platelet and red blood cell specific traits were predominantly found in the macrophages and erythroblasts, respectively 35, 56 . Thus, tissue-type specific promoter interactomes uncovered by PCHi-C may help to understand the function of non-coding disease-associated sequence variants and identify new potential disease genes for therapeutic intervention.
Characteristics of promoter-interacting regions
Several lines of evidence link promoter interactomes to gene expression control. First, several PCHi-C studies have demonstrated that genomic regions interacting with promoters of (highly) expressed genes are enriched in marks associated with enhancer activity, such as H3K27 acetylation and p300 binding 33, 34, 37 . We found a positive correlation between gene expression level and the number of interacting enhancers, suggesting that additive effects of enhancers result in increased gene expression levels 34, 35 . Second, naturally occurring expression quantitative trait loci (eQTLs) are enriched in PIRs that are connected to the same genes whose expression is affected by the eQTLs 35 . Third, by integrating TRIP 57 and PCHi-C data, Cairns et al. found that TRIP reporter genes mapping to PIRs in mouse ESCs show stronger reporter gene expression than reporter genes at integration sites in non-promoter-interacting regions 58 , indicating that PIRs possess transcriptional regulatory activity. Together, these findings suggest that promoter interactomes uncovered by PCHi-C in various mouse and human cell types include key regulatory modules for gene expression control.
It is worth noting that enhancers represent only a small fraction (~20%) of all PIRs uncovered by PCHi-C 33, 34 . Other PIRs could have structural or topological roles rather than direct transcriptional regulatory functions. However, there is also evidence that PCHi-C may uncover DNA elements with regulatory function that do not harbor classical enhancer marks. In a human lymphoid cell line, the BRD7 promoter was found to interact with a region devoid of enhancer marks that was shown to possess enhancer activity in reporter gene assays 33 . Regulatory elements with similar characteristics may be more abundant than currently appreciated. For example, a CRISPR-based screen for regulatory DNA elements identified unmarked regulatory elements (UREs) that control gene expression but are devoid of enhancer marks 59 .
In other cases, PIRs have been shown to harbor chromatin marks associated with transcriptional repression. PIRs and interacting promoters bound by PRC1 in mouse ESCs were engaged in an extensive spatial network of repressed genes bearing the repressive mark H3K27me3 7 . In human lymphoblastoid cells, a distant element interacting with the BCL6 promoter repressed transgene reporter gene expression 33 , suggesting that it may function to repress BCL6 transcription in its native context.
PIRs enriched for occupancy of the chromatin insulator protein CTCF in human ESCs and NECs 37 may represent yet another class of PIRs.
Collectively, these results suggest that PIRs harbor a collection of gene regulatory activities yet to be functionally characterized.
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